Abelson joel e - direct investment history in Talecris biotherapeutics holdings corp

Filed on 2011-06-03 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-015849.txt Sec File: edgar/data/1472088/0001225208-11-015849-index.htm

2011-06-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 96360.0000 shares remaining shares owned 0

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise date 2009-04-01 exercise price 11.0000 has valueitem expiration due date 2018-04-01 underlying security shares 96360.0000 underlying security title Common Stock

f3 this option, which was fully vested and exercisable, deemed subject to a cashless exercise pursuant to the merger agreement, and the net number of issuer shares deemed issued in connection with the deemed cashless exercise (after taking into account the exercise price of the option and applicable withholding taxes) were disposed of pursuant to the merger agreement in exchange for $19 in cash and 0.6485 grifols adss per issuer share deemed issued, with each grifols ads having a market value of $7.65 per grifols ads on the first trading day of the grifols adss following the effective date of the merger.


Filed on 2011-06-03 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-015849.txt Sec File: edgar/data/1472088/0001225208-11-015849-index.htm

2011-06-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 11755.0000 shares remaining shares owned 0

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise price 19.0000 has valueitem expiration due date 2019-09-30 underlying security shares 11755.0000 underlying security title Common Stock

f2 this option, which provided for vesting in three equal annual installments beginning april 1, 2011, deemed subject to a cashless exercise pursuant to the merger agreement, and the net number of issuer shares deemed issued in connection with the deemed cashless exercise (after taking into account the exercise price of the option and applicable withholding taxes) were disposed of pursuant to the merger agreement in exchange for $19 in cash and 0.6485 grifols adss per issuer share deemed issued, with each grifols ads having a market value of $7.65 per grifols ads on the first trading day of the grifols adss following the effective date of the merger.


Filed on 2011-06-03 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-015849.txt Sec File: edgar/data/1472088/0001225208-11-015849-index.htm

2011-06-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 8810 shares at $0 remaining shares owned 0

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: D Sale (or disposition) back to the issuer of the securities

f1 disposed of pursuant to the merger agreement between issuer, stream merger sub, inc., grifols, s.a., and grifols, inc. in exchange for $19.00 in cash and 0.6485 non-voting (class b) ordinary shares of grifols, s.a. (the grifols b shares) (in the form of american depository shares (the grifols ads); with each grifols ads representing one-half of one grifols b share) per issuer share, with each grifols ads having a market value of $7.65 per grifols ads on the first trading day of the grifols adss following the effective date of the merger.


Filed on 2011-04-05 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-011290.txt Sec File: edgar/data/1472088/0001225208-11-011290-index.htm

2011-04-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 1468 shares at $26.9400 remaining shares owned 8810

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f2 includes restricted share units representing the right to receive 3,948 shares of the issuer's common stock that will vest in equal annual installments on april 1, 2012 and april 1, 2013, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2011-04-05 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-011290.txt Sec File: edgar/data/1472088/0001225208-11-011290-index.htm

2011-04-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 4357 shares at $0.0000 remaining shares owned 10278

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: A Grant, award, or other acquisition

f1 the transaction reported in this row involves the settlement of performance share units into common stock that were granted pursuant to our 2009 long-term incentive plan.
f2 includes restricted share units representing the right to receive 3,948 shares of the issuer's common stock that will vest in equal annual installments on april 1, 2012 and april 1, 2013, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2011-02-02 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-004542.txt Sec File: edgar/data/1472088/0001225208-11-004542-index.htm

2011-02-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 15000.0000 shares at $11.0000 remaining shares owned 96360

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise date 2009-04-01 exercise price 11.0000 has valueitem expiration due date 2018-04-01 underlying security shares 15000.0000 underlying security title Common Stock

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f4 the option is fully vested and immediately exercisable.


Filed on 2011-02-02 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-004542.txt Sec File: edgar/data/1472088/0001225208-11-004542-index.htm

2011-02-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 15000 shares at $24.3810 remaining shares owned 5921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: S Open market or private sale of securities

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $24.26 to $24.46, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f2 the number of shares reported includes restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2011-02-02 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-004542.txt Sec File: edgar/data/1472088/0001225208-11-004542-index.htm

2011-02-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 15000 shares at $11.0000 remaining shares owned 20921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: M Exercise or conversion of derivative security

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f2 the number of shares reported includes restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2011-01-04 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-000574.txt Sec File: edgar/data/1472088/0001225208-11-000574-index.htm

2011-01-03 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 45000.0000 shares at $11.0000 remaining shares owned 111360

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise date 2009-04-01 exercise price 11.0000 has valueitem expiration due date 2018-04-01 underlying security shares 45000.0000 underlying security title Common Stock

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f4 the option is fully vested and immediately exercisable.


Filed on 2011-01-04 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-000574.txt Sec File: edgar/data/1472088/0001225208-11-000574-index.htm

2011-01-03 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 45000 shares at $23.0796 remaining shares owned 5921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: S Open market or private sale of securities

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $22.94 to $23.25, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f2 the number of shares reported includes restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2011-01-04 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-11-000574.txt Sec File: edgar/data/1472088/0001225208-11-000574-index.htm

2011-01-03 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 45000 shares at $11.0000 remaining shares owned 50921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: M Exercise or conversion of derivative security

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f2 the number of shares reported includes restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2010-10-04 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-022108.txt Sec File: edgar/data/1472088/0001225208-10-022108-index.htm

2010-10-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 30000.0000 shares at $11.0000 remaining shares owned 156360

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise date 2009-04-01 exercise price 11.0000 has valueitem expiration due date 2018-04-01 underlying security shares 30000.0000 underlying security title Common Stock

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f4 the option is fully vested and immediately exercisable.


Filed on 2010-10-04 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-022108.txt Sec File: edgar/data/1472088/0001225208-10-022108-index.htm

2010-10-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 30000 shares at $22.8172 remaining shares owned 5921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: S Open market or private sale of securities

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $22.76 to $22.92, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f2 the number of shares reported includes / consists of restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2010-10-04 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-022108.txt Sec File: edgar/data/1472088/0001225208-10-022108-index.htm

2010-10-01 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 30000 shares at $11.0000 remaining shares owned 35921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: M Exercise or conversion of derivative security

f1 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f2 the number of shares reported includes / consists of restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2010-08-31 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-020025.txt Sec File: edgar/data/1472088/0001225208-10-020025-index.htm

2010-08-27 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 8128 shares at $22.0863 remaining shares owned 5921

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: S Open market or private sale of securities

f2 the transaction reported was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f1 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $21.96 to $22.25, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f3 the number of shares reported consists of restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2010-08-26 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-019874.txt Sec File: edgar/data/1472088/0001225208-10-019874-index.htm

2010-08-25 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 105440.0000 shares at $11.0000 remaining shares owned 0

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise date 2007-04-01 exercise price 11.0000 has valueitem expiration due date 2016-12-06 underlying security shares 105440.0000 underlying security title Common Stock

f1 the transaction reported was effected purusant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f4 the option is fully vested and immediately exercisable.


Filed on 2010-08-26 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-019874.txt Sec File: edgar/data/1472088/0001225208-10-019874-index.htm

2010-08-25 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp remaining shares owned 186360

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise date 2009-04-01 exercise price 11.0000 has valueitem expiration due date 2018-04-01 underlying security shares 186360.0000 underlying security title Common Stock


Filed on 2010-08-26 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-019874.txt Sec File: edgar/data/1472088/0001225208-10-019874-index.htm

2010-08-25 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp remaining shares owned 11755

Options Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise price 19.0000 has valueitem expiration due date 2019-09-30 underlying security shares 11755.0000 underlying security title Common Stock

f5 option will vest in three equal annual installments beginning april 1, 2011, as detailed in a stock option award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2010-08-26 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-019874.txt Sec File: edgar/data/1472088/0001225208-10-019874-index.htm

2010-08-25 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp sold 105440 shares at $21.8893 remaining shares owned 14049

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: S Open market or private sale of securities

f1 the transaction reported was effected purusant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $21.81 to $21.96, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f2 the number of shares reported includes restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2010-08-26 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001225208-10-019874.txt Sec File: edgar/data/1472088/0001225208-10-019874-index.htm

2010-08-25 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 105440 shares at $11.0000 remaining shares owned 119489

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: M Exercise or conversion of derivative security

f1 the transaction reported was effected purusant to a rule 10b5-1 trading plan adopted by the reporting person on august 20, 2010.
f2 the number of shares reported includes restricted share units representing the right to receive 5,921 shares of the issuers common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2009-10-01 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001104659-09-057292.txt Sec File: edgar/data/1472088/0001104659-09-057292-index.htm

2009-09-30 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Port Int Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 11755 shares at $0 remaining shares owned 11755

Option Right To Buy Talecris Biotherapeutics Holdings Corp Tlcr exercise price 19 has valueitem expiration due date 2019-09-30 underlying security shares 11755 underlying security title Common Stock

f3 the transaction reported in this row involves a grant by the issuer to the reporting person of options to purchase the issuer's common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a stock option award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.


Filed on 2009-10-01 by Abelson Joel E SEC CIK 1472088 Form 4

Accession 0001104659-09-057292.txt Sec File: edgar/data/1472088/0001104659-09-057292-index.htm

2009-09-30 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Port Int Bus)

Invested in Talecris Biotherapeutics Holdings Corp bought 5921 shares at $0 remaining shares owned 14049

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr Transaction code: A Grant, award, or other acquisition

f1 the transaction reported in this row involves a grant by the issuer to the reporting person of restricted share units representing the right to receive 5,921 shares of the issuer's common stock that will vest in three equal annual installments beginning april 1, 2011, as detailed in a restricted share unit award agreement by and between the issuer and the reporting person, dated as of september 30, 2009.
f2 the number of shares reported includes 3,392 shares that have not yet vested of the issuer's common stock that were granted by the issuer to the reporting person on december 6, 2006 and which will vest on march 31, 2010, subject to the reporting person's continuous service with the issuer through that date, as detailed in a restricted stock award agreement by and between the issuer and the reporting person, dated as of december 6, 2006.


Filed on 2009-09-30 by Abelson Joel E SEC CIK 1472088 Form 3

Accession 0001104659-09-057130.txt Sec File: edgar/data/1472088/0001104659-09-057130-index.htm

2009-09-30 Abelson Joel E (CIK 1472088) through Direct (Sr Vp Gm Intl Bus)

Invested in Talecris Biotherapeutics Holdings Corp remaining shares owned 8128

Common Stock Talecris Biotherapeutics Holdings Corp Tlcr

f1 the number of shares reflected in this row includes 3,392 shares that have not yet vested of the issuer's common stock that were granted by the issuer to the reporting person on december 6, 2006 and which will vest on march 31, 2010, subject to the reporting person's continuous service with the issuer through that date, as detailed in a restricted stock award agreement by and between the issuer and the reporting person, dated as of december 6, 2006.